IDH1 and astrocytoma (excluding glioblastoma): Another recent study by Pandith et al investigated the relationship between IDH1/IDH2 mutations and MGMT methylation in patients receiving chemotherapies in different types of malignant gliomas (astrocytomas and oligodendrogliomas).